Brief: Ryvu Therapeutics Signs Annex To Start Phase II Clinical Trial
22/07/2026 16:10
BRIEF-Ryvu Therapeutics Signs Annex To Start Phase II Clinical Trial July 22 (Reuters) - Ryvu Therapeutics SA RVU.WA:
SIGNS AMENDMENT WITH MENARINI GROUP TO START PHASE II CLINICAL TRIAL OF DAPOLSERTIB IN MYELOFIBROSIS
Source text: https://tinyurl.com/mva5kssf
Further company coverage: RVU.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys